Skip to main content
All Posts By

cece

Targeted Oncology
Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC ResearchTreatments

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation…
cece
September 7, 2021
cancer therapy advisor
Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out ResearchTreatments

Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out

*July 2021* Note  Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment for advanced non-small cell lung cancer (NSCLC) is still unclear, according to researchers. Osimertinib is a standard first-line treatment option for patients with advanced NSCLC and EGFR mutations, but progression on this…
cece
September 7, 2021
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response ResearchTreatments

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation tyrosine kinase inhibitor, in both treatment-naïve and osimertinib (osi)-relapsed patients (pts) with EGFRm NSCLC (Cho Ann Oncol 2020;31:S813). We present updated results of the combination in osi-relapsed pts, including an…
cece
September 6, 2021
medpage today
Clinical Challenge: Optimal Therapies for Rare EGFR Mutations in NSCLC ResearchTreatments

Clinical Challenge: Optimal Therapies for Rare EGFR Mutations in NSCLC

*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung cancer (NSCLC) were first pinpointed in 2004. These mighty mutations have emerged as the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI) therapies, with deletions in exon 19 and the point…
cece
September 6, 2021
Aumolertinib vs Gefitinib for NSCLC EGFR exon 19 del or L858R mutations ResearchTreatments

Aumolertinib vs Gefitinib for NSCLC EGFR exon 19 del or L858R mutations

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. Au has been approved in China for treatment of patients (pts)…
cece
September 6, 2021
OncLive
Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC ResearchTreatments

Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC

*June 2021* Note: The CHRYSALIS Trial, involves a combination of amivantamab and lazertinib in patients with Tagrisso-relapsed and chemo naïve cancer. Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the updated results of the…
cece
September 6, 2021
Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC ResearchTreatments

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

*April 2021* Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated patients. Dr. Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors. Watch…
cece
September 6, 2021
New EGFR Resisters Multi-Year Research Partnership with Lung Cancer Research Foundation (LCRF) AdvocacyFundingPartners

New EGFR Resisters Multi-Year Research Partnership with Lung Cancer Research Foundation (LCRF)

*June 2021* The EGFR Resisters is thrilled to announce a new multi-year research partnership with Lung Cancer Research Foundation (LCRF)!  LCRF is a large non-profit lung cancer advocacy organization based in New York whose mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and…
cece
June 24, 2021
JTO Clinical and Research Reports
Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report ResearchTreatments

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed in combination with osimertinib. This builds on the limited data evaluating…
cece
June 24, 2021